Infectious Diseases (all articles)
Review | Respiratory viruses: their importance and lessons learned from COVID-19.
7 Nov, 2022 | 11:54h | UTC
A multinational Delphi consensus to end the COVID-19 public health threat.
4 Nov, 2022 | 14:01h | UTCA multinational Delphi consensus to end the COVID-19 public health threat – Nature
Perspective | Monkeypox — A sobering sentinel for pandemic preparedness and sexual health system capacity.
4 Nov, 2022 | 13:53h | UTCRelated:
Monkeypox – New England Journal of Medicine
Monkeypox: disease epidemiology, host immunity and clinical interventions.
Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health
CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.
Update on the Monkeypox Outbreak – JAMA
WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch
Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases
Commentary on Twitter
The monkeypox pandemic has highlighted lessons learned — and sometimes ignored — from Covid-19 and has illustrated the inadequacy of sexual health infrastructure and pandemic preparedness in the United States. https://t.co/jXuYoH9Wn2 pic.twitter.com/KcTqBuyEXi
— NEJM (@NEJM) November 2, 2022
Cohort Study | Covid-19 vaccine effectiveness among children and adolescents in Qatar.
4 Nov, 2022 | 13:51h | UTC
Commentary on Twitter
The 10-µg dose of BNT162b2 led to modest, rapidly waning protection against Covid-19 in children 5 to 11 years old. The 30-µg dose in adolescents gave greater, more durable protection; more so in 12-to-14-year-olds than in 15-to-17-year-olds. https://t.co/ddcqiR8jvO pic.twitter.com/M8oSFYoFlw
— NEJM (@NEJM) November 2, 2022
RCT | Clinical and cost-effectiveness of single stage compared vs. two-stage revision for hip prosthetic joint infection.
4 Nov, 2022 | 13:49h | UTC
RCT | Oral antimicrobial prophylaxis reduced surgical site infection after elective colorectal surgery.
4 Nov, 2022 | 13:48h | UTC
Brief Review | Close collaboration between pathologists and intensivists to understand (not just) coronavirus disease.
4 Nov, 2022 | 13:37h | UTC
Commentary on Twitter
Pathologists & intensivists collaborating to understand (not just) #COVID19
➡️ facing an unknown entity: challenge in #ICU
➡️ lightening pathophysiological shadow: demand for autopsies
➡️ formalizing interdisciplinary exchange to optimize outcome#FOAMcc
?️https://t.co/0a48Vontzn pic.twitter.com/K9zTl5b8vp— Intensive Care Medicine (@yourICM) November 2, 2022
M-A | Effect of pulmonary rehabilitation in dyspnea, exercise capacity, fatigue, and quality of life in patients with COVID-19.
3 Nov, 2022 | 14:09h | UTC
Comparative risk of thrombosis with thrombocytopenia or thromboembolic events with different covid-19 vaccines.
3 Nov, 2022 | 14:10h | UTC
Phase 2 RCT | A single injection of a monoclonal antibody was 88% effective for malaria prevention over 6 months.
2 Nov, 2022 | 14:30h | UTCSafety and Efficacy of a Monoclonal Antibody against Malaria in Mali – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Monoclonal antibody prevents malaria infection in African adults – National Institutes of Health
Commentary: Monoclonal antibody infusion 88% effective against malaria – CIDRAP
Related Study: Phase 1 Study | Low-dose subcutaneous or intravenous monoclonal antibody can prevent malaria in a human challenge model.
Commentary on Twitter
In this phase 2 trial in Mali, an antimalarial monoclonal antibody (CIS43LS) at the higher dose (40 mg per kilogram) was approximately 88% effective at preventing P. falciparum infection as compared with placebo. #TropMed22 https://t.co/UGeBHOPhKY pic.twitter.com/uFX7w3qV0G
— NEJM (@NEJM) November 1, 2022
RCT | Povidone-iodine and chlorhexidine gluconate are similarly effective for preventing SSI in open fractures.
2 Nov, 2022 | 14:27h | UTCAqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial – The Lancet (link to abstract – $ for full-text)
Related:
Antiseptic Skin Agents to Prevent Surgical Site Infection After Incisional Surgery: A Randomized, Three-armed Combined Non-inferiority and Superiority Clinical Trial (NEWSkin Prep Study) – Annals of Surgery (link to abstract – $ for full-text)
RCT | Efficacy of RBX2660 for preventing recurrent Clostridioides difficile after antibiotic treatment.
1 Nov, 2022 | 12:07h | UTCCommentary: RBX2660 shows promise in breaking the cycle of recurrent C. difficile – MDedge
RCT | A digital medication event reminder may improve quality of life and reduce costs in patients with tuberculosis.
1 Nov, 2022 | 11:48h | UTCCommentaries:
Digital Medication Device Improves Quality of Life, Reduces Costs for TB Patients – HCP Live
Digital Medication Monitor Linked to Better HRQOL, Lower Costs for Tuberculosis – AJMC
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1570442333686042628
WHO Report | Fungal priority pathogens list to guide research, development and public health action.
28 Oct, 2022 | 13:31h | UTCNews Release: WHO releases first-ever list of health-threatening fungi – World Health Organization
Commentary on Twitter (thread – click for more)
Fungal pathogens can cause illnesses and death.
They are becoming increasingly common and resistant to treatment.Yet, too little is known about them.
The ? WHO fungal priority pathogens list is an important step to boost urgently needed research:
? https://t.co/cXgj2HPZIc pic.twitter.com/4LgdIqf4Lo— World Health Organization (WHO) (@WHO) October 25, 2022
CDC study shows healthcare workers have a low risk of infection after exposure to patients with monkeypox.
28 Oct, 2022 | 13:21h | UTCCommentaries:
Clinicians at Low Risk of Acquiring Monkeypox From Patients – JAMA
Low risk of monkeypox spread noted in health workers – CIDRAP
Risk of Monkeypox Transmission Low in Health Care Settings – HealthDay
RCT | Selective decontamination of the GI tract did not significantly reduce mortality in ICU patients on mechanical ventilation.
27 Oct, 2022 | 12:40h | UTCEffect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
Related study: Association Between Selective Decontamination of the Digestive Tract and In-Hospital Mortality in Intensive Care Unit Patients Receiving Mechanical Ventilation: A Systematic Review and Meta-analysis – JAMA (free for a limited period)
M-A | Selective decontamination of the GI tract may reduce in-hospital mortality in ICU patients receiving mechanical ventilation.
27 Oct, 2022 | 12:39h | UTCAssociation Between Selective Decontamination of the Digestive Tract and In-Hospital Mortality in Intensive Care Unit Patients Receiving Mechanical Ventilation: A Systematic Review and Meta-analysis – JAMA (free for a limited period)
Related Study: Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial – JAMA (free for a limited period)
Review | Monkeypox.
27 Oct, 2022 | 12:36h | UTCMonkeypox – New England Journal of Medicine
Related:
Monkeypox: disease epidemiology, host immunity and clinical interventions.
Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health
CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.
Update on the Monkeypox Outbreak – JAMA
WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch
Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases
Commentary on Twitter
Monkeypox cases reported in the United Kingdom, Portugal, and Italy in May 2022 led the WHO to declare a global health emergency. The authors review the virology, epidemiology, clinical features, and treatment of monkeypox. https://t.co/dk2ZxxPsN7 pic.twitter.com/u3gzD6V7Bo
— NEJM (@NEJM) October 26, 2022
RCT | Ivermectin does not improve time to recovery in outpatients with mild to moderate COVID-19.
24 Oct, 2022 | 14:14h | UTCCommentary: Ivermectin doesn’t speed time to recovery from nonsevere COVID – CIDRAP
Commentary on Twitter
Study findings do not support the use of #ivermectin in outpatients with mild to moderate #COVID19. https://t.co/do8zbVkeLK #Research
— JAMA (@JAMA_current) October 21, 2022
Post-trial follow-up | Microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection.
24 Oct, 2022 | 14:15h | UTCExtended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, durably reduced recurrent Clostridioides difficile infection rates and was well-tolerated through 24 weeks in patients with prevalent comorbidities. https://t.co/abayN0iJ5z
— JAMA (@JAMA_current) October 19, 2022
RCT | Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age.
20 Oct, 2022 | 12:35h | UTC
Commentary on Twitter
Randomized, placebo-controlled trial of the 2-dose @moderna_tx vaccine in children 6 months to 5 years, during Omicron. Safe in ~4,800 kids; good immune response; efficacy vs infections ?https://t.co/DkLXAQQaeZ @NEJM pic.twitter.com/ettWOnDGQf
— Eric Topol (@EricTopol) October 19, 2022
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
20 Oct, 2022 | 12:34h | UTCMyocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine
Commentary on Twitter
Among Israeli adolescents between 12 and 15 years of age who received the BNT162b2 vaccine, 9 cases of mild myocarditis were observed, mainly after the second dose. https://t.co/OatYqN4IPD pic.twitter.com/c96d1o7wnt
— NEJM (@NEJM) October 19, 2022
Pooled analysis of cohort studies | Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters.
19 Oct, 2022 | 14:28h | UTCCommentaries:
Prioritisation of COVID-19 boosters in the omicron era – The Lancet
COVID booster halved severe illness, but some groups still at higher risk – CIDRAP
RCT | Efficacy of BCG vaccination in reducing the incidence and severity of COVID-19 in a high-risk population.
19 Oct, 2022 | 14:26h | UTC
Case-control study | Odds of hospitalization for COVID-19 after 3 vs. 2 doses of mRNA vaccine by time since booster dose.
19 Oct, 2022 | 14:27h | UTC